Aktienanalyse zu Lyell Immunopharma Inc (LYEL)LYELLyell Immunopharma Inc

Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Lyell Immunopharma is a good buy right now due to its current price of $14.53, which is significantly lower than analyst price targets of $44 and $49, indicating substantial upside potential. The recent reduction in net loss to $24.2 million in Q1 2026 from $52.2 million in Q1 2025 shows improved operational efficiency, which can attract more investor confidence. However, the main risk lies in its high net loss of $140.7 million reported in Q4 2025, which reflects ongoing financial challenges.